Portrazza is a recombinant human monoclonal antibody that binds to EGFR1

EGFR is expressed in 84%-95% of squamous NSCLC2,3

Portrazza MOA graphic
Zoom In
Zoom Out

Portrazza in combination with gemcitabine and cisplatin has demonstrated antitumor activity in an in vivo animal model of NSCLC.1

EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer.

References: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015. 2. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol. 2002;29(5 suppl 14):38-44. 3. Supplement to: Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-774. 4. Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther. 2011;11(9):1223-1231. 5. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7(suppl 4):2-8.